Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrimethamine + sulfadiazine + folinate for disseminated toxoplasmosis and toxoplasma encephalitis
jRCTs071180095Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Mar 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of pyrimethamine, Sulfadiazine and folinic acid in Disseminated Toxoplasmosis and cerebral toxoplasmosis (TE), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Survival rate at 6 weeks. Started Mar 2020; status: recruiting.
02
Drugs
pyrimethamineSulfadiazinefolinic acid
03
Conditions
Disseminated Toxoplasmosiscerebral toxoplasmosis (TE)
Beyond the preview
Go deeper on jRCTs071180095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071180095.